Haopeng Sun[Author] - Search Results

Year	Number of Results
2011	3
2012	9
2013	15
2014	15
2015	10
2016	9
2017	7
2018	19
2019	16
2020	23
2021	20
2022	18
2023	16
2024	5

1

Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.

Shen H, Xu X, Bai Y, Wang X, Wu Y, Zhong J, Wu Q, Luo Y, Shang T, Shen R, Xi M, Sun H. Shen H, et al. Among authors: sun h. Eur J Med Chem. 2023 May 5;251:115258. doi: 10.1016/j.ejmech.2023.115258. Epub 2023 Mar 8. Eur J Med Chem. 2023. PMID: 36917881 Review.

2

Degradation of proteins by PROTACs and other strategies.

Wang Y, Jiang X, Feng F, Liu W, Sun H. Wang Y, et al. Among authors: sun h. Acta Pharm Sin B. 2020 Feb;10(2):207-238. doi: 10.1016/j.apsb.2019.08.001. Epub 2019 Aug 13. Acta Pharm Sin B. 2020. PMID: 32082969 Free PMC article. Review.

3

G9a - An Appealing Antineoplastic Target.

Chen WL, Sun HP, Li DD, Wang ZH, You QD, Guo XK. Chen WL, et al. Curr Cancer Drug Targets. 2017;17(6):555-568. doi: 10.2174/1568009616666160512145303. Curr Cancer Drug Targets. 2017. PMID: 27174055 Review.

4

Editorial: Pharmaceutical insights into the triazoles: Recent advances.

Deng X, Sun H, Youssif BGM. Deng X, et al. Among authors: sun h. Front Chem. 2023 Feb 1;11:1149133. doi: 10.3389/fchem.2023.1149133. eCollection 2023. Front Chem. 2023. PMID: 36817176 Free PMC article. No abstract available.

5

Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.

Chen T, Tang X, Wang Z, Feng F, Xu C, Zhao Q, Wu Y, Sun H, Chen Y. Chen T, et al. Among authors: sun h. Eur J Med Chem. 2023 Dec 5;261:115828. doi: 10.1016/j.ejmech.2023.115828. Epub 2023 Sep 25. Eur J Med Chem. 2023. PMID: 37778239 Review.

6

The recent progress of isoxazole in medicinal chemistry.

Zhu J, Mo J, Lin HZ, Chen Y, Sun HP. Zhu J, et al. Bioorg Med Chem. 2018 Jul 23;26(12):3065-3075. doi: 10.1016/j.bmc.2018.05.013. Epub 2018 May 28. Bioorg Med Chem. 2018. PMID: 29853341 Review.

7

Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds.

Qiu W, Liu H, Liu Y, Lu X, Wang L, Hu Y, Feng F, Li Q, Sun H. Qiu W, et al. Among authors: sun h. Med Res Rev. 2023 Jul;43(4):1091-1140. doi: 10.1002/med.21947. Epub 2023 Mar 21. Med Res Rev. 2023. PMID: 36945751 Review.

8

Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

Liu Y, He S, Chen Y, Liu Y, Feng F, Liu W, Guo Q, Zhao L, Sun H. Liu Y, et al. Among authors: sun h. J Med Chem. 2020 Oct 22;63(20):11305-11329. doi: 10.1021/acs.jmedchem.9b02138. Epub 2020 Jun 10. J Med Chem. 2020. PMID: 32463235 Review.

9

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.

Cao R, Chen C, Wen J, Zhao W, Zhang C, Sun L, Yuan L, Wu C, Shan L, Xi M, Sun H. Cao R, et al. Among authors: sun h. Bioorg Chem. 2023 Dec;141:106906. doi: 10.1016/j.bioorg.2023.106906. Epub 2023 Oct 7. Bioorg Chem. 2023. PMID: 37837728 Review.

10

Medicinal Prospects of Targeting Tyrosinase: A Feature Review.

Wang Y, Xiong B, Xing S, Chen Y, Liao Q, Mo J, Chen Y, Li Q, Sun H. Wang Y, et al. Among authors: sun h. Curr Med Chem. 2023;30(23):2638-2671. doi: 10.2174/0929867329666220915123714. Curr Med Chem. 2023. PMID: 36111760 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

162 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year